Company intelligence / Profile preview

Saol Therapeutics Research

Dublin, Dublin, Ireland

Ownership: Private
Employees: ~39
Development stage: Other

Overview

SL1009 (sodium dichloroacetate) completed Phase 3 for PDCD; awaiting FDA NDA decision August 2025. Has Orphan Drug, Fast Track, and Rare Pediatric Disease designations. SL1002 advancing toward Phase 3 in osteoarthritis knee pain; spasticity data shows positive clinical signals.

Therapeutic areas: NeurologyMetabolic DisordersRheumatology
Modalities: Small moleculeInjectable therapy
Industry: Biotech

Partnerships

Medosome Biotec (companion diagnostic for PDCD/DCA program)

Beyond the preview

Go deeper on Saol Therapeutics Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saol Therapeutics Research.

Explore the full profile